Trial Profile

Optimal Dosing of Oral Anticancer Drugs in Older Adults With Cancer: a Randomized Pilot Study.

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Pazopanib (Primary) ; Sunitinib (Primary)
Indications Breast cancer; Carcinoma; Endometrial cancer; Ovarian cancer; Renal cancer; Thyroid cancer
Focus Adverse reactions
Acronyms OPTI-DOSE

Most Recent Events

28 Nov 2023 Planned initiation date changed from 1 Sep 2023 to 1 May 2024.
20 Jul 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com